Abstract: An example embodiment may include a computational instance and a computing device within a remote network management platform. The computing device may be configured to: receive, from a client device of the managed network, a request to redirect, to a second URL, future requests addressed to a first URL; provide, to the client device, instructions to generate a certificate that binds an identity of the entity that operates the managed network to the first URL; receive, from the client device, the certificate; store the certificate and a corresponding cryptographic key; and generate a mapping between the first URL and the second URL. The computational instance may be configured to, in response to receiving a content request referencing the destination, generate a content response containing content from the destination, where any hyperlinks to the second URL in the content are replaced with hyperlinks to the first URL.

Abstract: An example embodiment may include a computational instance and a computing device within a remote network management platform. The computing device may be configured to: receive, from a client device of the managed network, a request to redirect, to a second URL, future requests addressed to a first URL; provide, to the client device, instructions to generate a certificate that binds an identity of the entity that operates the managed network to the first URL; receive, from the client device, the certificate; store the certificate and a corresponding cryptographic key; and generate a mapping between the first URL and the second URL. The computational instance may be configured to, in response to receiving a content request referencing the destination, generate a content response containing content from the destination, where any hyperlinks to the second URL in the content are replaced with hyperlinks to the first URL.

Abstract: An example embodiment may include a computational instance and a computing device within a remote network management platform. The computing device may be configured to: receive, from a client device of the managed network, a request to redirect, to a second URL, future requests addressed to a first URL; provide, to the client device, instructions to generate a certificate that binds an identity of the entity that operates the managed network to the first URL; receive, from the client device, the certificate; store the certificate and a corresponding cryptographic key; and generate a mapping between the first URL and the second URL. The computational instance may be configured to, in response to receiving a content request referencing the destination, generate a content response containing content from the destination, where any hyperlinks to the second URL in the content are replaced with hyperlinks to the first URL.

Abstract: An example embodiment may include a computational instance and a computing device within a remote network management platform. The computing device may be configured to: receive, from a client device of the managed network, a request to redirect, to a second URL, future requests addressed to a first URL; provide, to the client device, instructions to generate a certificate that binds an identity of the entity that operates the managed network to the first URL; receive, from the client device, the certificate; store the certificate and a corresponding cryptographic key; and generate a mapping between the first URL and the second URL. The computational instance may be configured to, in response to receiving a content request referencing the destination, generate a content response containing content from the destination, where any hyperlinks to the second URL in the content are replaced with hyperlinks to the first URL.

Abstract: HSulf-1 nucleic acids and polypeptides are provided, as are methods of using the nucleic acids and polypeptides.

Abstract: The present invention relates to a combination of (a) an ATP-competitive inhibitor of Bcr/abl kinase activity and (b)) a tyrphostin analog, and the use of said combination or product for the treatment of bcr/abl-related diseases.

Abstract: This invention provides the use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) in the treatment or inhibition of mantle cell lymphoma.